Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Screening and testing for monoclonal gammopathies: Lessons from the iStopMM screening study​

Since its introduction in 2002, serum free light chains (sFLC) testing has become a key laboratory parameter for diagnosis and management of monoclonal gammopathies. Currently, several immunoassays for determination of sFLC assays are commercially available, of which some designs employ polyclonal antibodies and others monoclonal antibodies, resulting in different value reporting.

This webinar covers the clinical and laboratory aspects that affect serum free light chains testing in diagnosis and monitoring of monoclonal gammopathies, especially with regard to patients with renal impairment and possible misclassification of patients.

2024-11-07
Dr. Sæmundur Rögnvaldsson, Physician and post-doctoral researcher at the University of Iceland and Landspítali—The National University Hospital of Iceland

Dr. Sæmundur Rögnvaldsson, Iceland
Physician and post-doctoral researcher at the University of Iceland and Landspítali—The National University Hospital of Iceland